MCID: CNN001
MIFTS: 37

Cannabis Dependence

Categories: Mental diseases

Aliases & Classifications for Cannabis Dependence

Summaries for Cannabis Dependence

Disease Ontology : 12 A drug dependence that involves the continued use of cannabis despite problems related to use of the substance.

MalaCards based summary : Cannabis Dependence, also known as marijuana abuse, is related to personality disorder and cannabis abuse. An important gene associated with Cannabis Dependence is CNR1 (Cannabinoid Receptor 1), and among its related pathways/superpathways are GABAergic synapse and Neuroscience. The drugs Ethanol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and amygdala, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Cannabis Dependence

Graphical network of the top 20 diseases related to Cannabis Dependence:



Diseases related to Cannabis Dependence

Symptoms & Phenotypes for Cannabis Dependence

MGI Mouse Phenotypes related to Cannabis Dependence:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.5 PENK ABCB1 CNR1 COMT FAAH HCRT
2 homeostasis/metabolism MP:0005376 9.17 ABCB1 CNR1 COMT FAAH HCRT MGLL

Drugs & Therapeutics for Cannabis Dependence

Drugs for Cannabis Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
2
Dopamine Approved Phase 4,Phase 2,Early Phase 1 51-61-6, 62-31-7 681
3
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 616-91-1 12035
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
6
Nicotine Approved Phase 4,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
7
Clozapine Approved Phase 4 5786-21-0 2818
8
Fluoxetine Approved, Vet_approved Phase 4,Phase 2 54910-89-3 3386
9
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
10 Antipsychotic Agents Phase 4,Phase 2
11 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
12 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
13 Quetiapine Fumarate Phase 4,Phase 2 111974-72-2
14 Tranquilizing Agents Phase 4,Phase 2,Phase 3,Early Phase 1
15 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
16
Serotonin Phase 4,Phase 2 50-67-9 5202
17 Serotonin Agents Phase 4,Phase 2
18 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
19 Central Nervous System Stimulants Phase 4,Phase 2,Phase 1
20 Cholinergic Agents Phase 4,Phase 2,Phase 1
21 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
22 Serotonin Antagonists Phase 4
23 Antidepressive Agents Phase 4,Phase 2
24 Antidepressive Agents, Second-Generation Phase 4,Phase 2
25 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
26 Serotonin Uptake Inhibitors Phase 4,Phase 2
27 Dopamine Agents Phase 4,Phase 2,Early Phase 1
28 Antidotes Phase 4,Phase 3,Phase 2,Phase 1
29 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
30 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1
31 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Expectorants Phase 4,Phase 3,Phase 2,Phase 1
33 N-monoacetylcystine Phase 4,Phase 3,Phase 2,Phase 1
34 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Dopamine Antagonists Phase 4
37 Anti-Anxiety Agents Phase 4,Phase 2,Phase 3,Early Phase 1
38 Nicotinic Agonists Phase 4,Phase 2,Phase 1
39 GABA Agents Phase 4,Phase 2,Phase 1
40 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
41 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
42 Dopamine Uptake Inhibitors Phase 4,Phase 2
43
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
44
Dronabinol Approved, Illicit Phase 2, Phase 3, Phase 1, Early Phase 1 1972-08-3 16078 2978
45
Lofexidine Approved, Investigational Phase 2, Phase 3 31036-80-3 30668
46
Nabilone Approved, Investigational Phase 2, Phase 3 51022-71-0 5284592
47
Ketamine Approved, Vet_approved Phase 2, Phase 3 6740-88-1 3821
48
Imidacloprid Vet_approved Phase 3 105827-78-9 86418
49 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 1
50 Narcotic Antagonists Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 109)

id Name Status NCT ID Phase Drugs
1 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Unknown status NCT01153490 Phase 4
2 Buspirone Treatment for Marijuana Dependence Completed NCT00875836 Phase 4 Buspirone;Placebo
3 Nicotine Patch for Marijuana Withdrawal Completed NCT01400243 Phase 4 Nicotine;Placebo Patch
4 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
5 Substance Dependent Teens - Impact of Treating Depression Study 1 - 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
6 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4 Bupropion
7 N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms Recruiting NCT03221231 Phase 4 N-acetylcysteine;Placebo Oral Tablet
8 Clozapine for Cannabis Use in Schizophrenia Active, not recruiting NCT01639872 Phase 4 Clozapine;Risperidone
9 A Comparison of Adolescent Group Therapy and Transitional Family Therapy for Adolescent Alcohol and Drug Abusers Unknown status NCT00484367 Phase 2, Phase 3
10 Combined Pharmacotherapy for Cannabis Dependency Completed NCT01020019 Phase 2, Phase 3 Dronabinol;Placebo;Lofexidine
11 Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment Completed NCT01675661 Phase 3 N-Acetylcysteine;Placebo
12 Nabilone & Marijuana Addiction Completed NCT01025700 Phase 2, Phase 3 Cesemat
13 Teen Marijuana Check-Up Completed NCT01109563 Phase 3
14 Nabilone for Cannabis Dependence: A Pilot Study Recruiting NCT01347762 Phase 2, Phase 3 Nabilone;Placebo
15 Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Recruiting NCT01598896 Phase 2, Phase 3 Dronabinol;Clonidine;Placebo
16 Facilitating the Behavioral Treatment of Cannabis Use Disorder Recruiting NCT02946489 Phase 2, Phase 3 CI-581a
17 A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana Unknown status NCT01005810 Phase 2 N-Acetylcysteine;placebo
18 Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction Unknown status NCT00543036 Phase 1, Phase 2
19 Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal Unknown status NCT01439828 Phase 2 N-acetylcystein
20 Quetiapine Pharmacotherapy for Cannabis Dependence Completed NCT01697709 Phase 2 Quetiapine;Placebo
21 Study of Quetiapine Treatment for Cannabis Dependence Completed NCT00954681 Phase 2 quetiapine
22 Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence Completed NCT01292642 Phase 2 Nicotine Replacement Therapy
23 Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence Completed NCT01747850 Phase 2 Sativex;Placebo spray
24 Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence Completed NCT02088177 Phase 1, Phase 2 Long-acting injectable naltrexone
25 Atomoxetine for the Treatment of Cannabis Dependence Completed NCT00167297 Phase 2 Atomoxetine
26 Gabapentin Treatment of Cannabis Dependence Completed NCT00974376 Phase 2 gabapentin 1200mg/day;Placebo
27 Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults Completed NCT00656487 Phase 2 rimonabant;placebo
28 Gabapentin Treatment of Cannabis Dependence Completed NCT00395044 Phase 2 Placebo;Gabapentin
29 Vilazodone Treatment for Marijuana Dependence Completed NCT01574183 Phase 2 Vilazodone;Placebo
30 Baclofen Effects on Marijuana Dependence Completed NCT02011516 Phase 2 Baclofen;Placebo
31 Dronabinol Treatment for Marijuana Addiction Completed NCT00217971 Phase 2 Dronabinol;Placebo
32 Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1 Completed NCT00131456 Phase 2 Venlafaxine;Placebo
33 Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1 Completed NCT00149617 Phase 2 Buspirone
34 Atomoxetine Treatment for ADHD and Marijuana Dependence Completed NCT00360269 Phase 2 Atomoxetine;Placebo
35 Treatment for Cannabis Withdrawal and Dependence Completed NCT01611948 Phase 2 Aprepitant;Placebo
36 Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1 Completed NCT00218517 Phase 2 Selegiline hydrochloride;Placebo
37 Pregnenolone and Marijuana Dependence Completed NCT02439814 Phase 2 Pregnenolone
38 A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence Completed NCT00360191 Phase 2 Buspirone
39 Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence Completed NCT00149643 Phase 2 Fluoxetine
40 An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents Completed NCT00542750 Phase 1, Phase 2 N-Acetylcysteine
41 Effect of Baclofen on Marijuana Withdrawal and Relapse Completed NCT00373295 Phase 2 Baclofen;Marijuana;Placebo
42 Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals Completed NCT00158249 Phase 2 citicoline;placebo
43 Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence Completed NCT02210195 Phase 2 aprepitant;Placebo
44 Lithium Cannabis Withdrawal Study Completed NCT00114439 Phase 2 Lithium carbonate
45 The Teen Marijuana Check-Up Completed NCT00350285 Phase 2
46 Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents Completed NCT01110434 Phase 2 Topiramate;Placebo
47 Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse Completed NCT00373503 Phase 2 Lofexidine;dronabinol;Marijuana
48 Comparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper Completed NCT00374127 Phase 2 Marijuana blunt;marijuana cigarette
49 Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal Completed NCT00480441 Phase 2 Dronabinol;Placebo
50 Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management Completed NCT00350649 Phase 2

Search NIH Clinical Center for Cannabis Dependence

Cochrane evidence based reviews: marijuana abuse

Genetic Tests for Cannabis Dependence

Anatomical Context for Cannabis Dependence

MalaCards organs/tissues related to Cannabis Dependence:

39
Brain, Testes, Amygdala

Publications for Cannabis Dependence

Articles related to Cannabis Dependence:

(show top 50) (show all 136)
id Title Authors Year
1
Social cognitive predictors of treatment outcome in cannabis dependence. ( 27883947 )
2017
2
Greater Prevalence of Proposed ICD-11 Alcohol and Cannabis Dependence Compared to ICD-10, DSM-IV, and DSM-5 in Treated Adolescents. ( 28667763 )
2017
3
Whole genome sequence study of cannabis dependence in two independent cohorts. ( 28111843 )
2017
4
Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study. ( 28921814 )
2017
5
S100A10 identified in a genome-wide gene A9 cannabis dependence interaction analysis of risky sexual behaviours. ( 28418321 )
2017
6
Treatment seeking in cannabis dependence: The role of social cognition. ( 27894043 )
2017
7
Genome-wide Significant Associations for Cannabis Dependence Severity: Relevance to Psychiatric Disorders. ( 27027914 )
2016
8
Persistent cannabis dependence and alcohol dependence represent risks for midlife economic and social problems: A longitudinal cohort study. ( 28008372 )
2016
9
Anxiety Sensitivity and Distress Intolerance as Predictors of Cannabis Dependence Symptoms, Problems, and Craving: The Mediating Role of Coping Motives. ( 27797690 )
2016
10
Vilazodone for cannabis dependence: A randomized, controlled pilot trial. ( 26685701 )
2016
11
Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series. ( 27261670 )
2016
12
Deficits in striatal dopamine release in cannabis dependence. ( 27001613 )
2016
13
Differential effects of cannabis dependence on cortical inhibition in patients with schizophrenia and non-psychiatric controls. ( 27964871 )
2016
14
Genome-wide Association Study of Cannabis Dependence Severity, Novel Risk Variants, and Shared Genetic Risks. ( 27028160 )
2016
15
Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. ( 26386827 )
2015
16
Three-Year Course of Cannabis Dependence and Prediction of Persistence. ( 26044258 )
2015
17
Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. ( 26595473 )
2015
18
Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. ( 26213314 )
2015
19
Risk-taking in schizophrenia and controls with and without cannabis dependence. ( 25467541 )
2015
20
Impact of age at onset of cannabis use on cannabis dependence and driving under the influence in the United States. ( 25543035 )
2015
21
Psychosocial Determinants of Cannabis Dependence: A Systematic Review of the Literature. ( 26551358 )
2015
22
Maintenance Check-ups Following Treatment for Cannabis Dependence. ( 25922136 )
2015
23
Associations between cigarette smoking and cannabis dependence: a longitudinal study of young cannabis users in the United Kingdom. ( 25622777 )
2015
24
Concordance of Direct and Indirect Measures of Medication Adherence in A Treatment Trial for Cannabis Dependence. ( 26028133 )
2015
25
Reliability and validity of the Marijuana Motives Measure among young adult frequent cannabis users and associations with cannabis dependence. ( 25240105 )
2014
26
Pretreatment measures of brain structure and reward-processing brain function in cannabis dependence: an exploratory study of relationships with abstinence during behavioral treatment. ( 24793365 )
2014
27
Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. ( 24628797 )
2014
28
Imaging dopamine transmission parameters in cannabis dependence. ( 24513022 )
2014
29
The Moderating Role of Experiential Avoidance in the Relationship between Posttraumatic Stress Disorder Symptom Severity and Cannabis Dependence. ( 25478317 )
2014
30
Pharmacotherapies for cannabis dependence. ( 25515775 )
2014
31
Baclofen in the management of cannabis dependence syndrome. ( 24490032 )
2014
32
Different dopaminergic abnormalities underlie cannabis dependence and cannabis-induced psychosis. ( 24560431 )
2014
33
Open-label pilot study of quetiapine treatment for cannabis dependence. ( 24963729 )
2014
34
Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. ( 24359507 )
2014
35
Potential use of Magnolia officinalis bark polyphenols in the treatment of cannabis dependence. ( 25459131 )
2014
36
Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. ( 23617872 )
2013
37
Cannabis dependence, cognitive control and attentional bias for cannabis words. ( 24018225 )
2013
38
CB1 and CB2 receptor expression and promoter methylation in patients with cannabis dependence. ( 22948261 )
2013
39
Reliability and validity of the Severity of Dependence Scale for detecting cannabis dependence in frequent cannabis users. ( 23670783 )
2013
40
Facilitators and barriers in treatment seeking for cannabis dependence. ( 24035185 )
2013
41
Plasma Cannabinoid Concentrations During Dronabinol Pharmacotherapy for Cannabis Dependence. ( 24067260 )
2013
42
Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. ( 23886472 )
2013
43
Cognitive behavioral therapy and the nicotine transdermal patch for dual nicotine and cannabis dependence: a pilot study. ( 23617864 )
2013
44
Multidimensional family therapy lowers the rate of cannabis dependence in adolescents: a randomised controlled trial in Western European outpatient settings. ( 23140805 )
2013
45
Palmitoylethanolamide: from endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence. ( 23896215 )
2013
46
A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. ( 23297841 )
2013
47
A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. ( 23187069 )
2013
48
Combining cognitive behavioral therapy and contingency management to enhance their effects in treating cannabis dependence: less can be more, more or less. ( 22404223 )
2012
49
Depression symptoms associated with cannabis dependence in an adolescent American Indian community sample. ( 23082832 )
2012
50
Use of aripiprazole in treatment of cannabis dependence in a patient presenting with Borderline Personality Disorder. ( 22772696 )
2012

Variations for Cannabis Dependence

Expression for Cannabis Dependence

Search GEO for disease gene expression data for Cannabis Dependence.

Pathways for Cannabis Dependence

Pathways related to Cannabis Dependence according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.95 CNR1 FAAH MGLL
2 11.84 CNR1 COMT HCRT
3 11.6 ABCB1 CNR1 FAAH
4
Show member pathways
11.07 ABCB1 COMT
5 10.07 CNR1 FAAH

GO Terms for Cannabis Dependence

Cellular components related to Cannabis Dependence according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell body GO:0044297 9.16 COMT NRG1
2 dendrite GO:0030425 9.13 COMT NRG1 PENK
3 axon GO:0030424 8.92 CNR1 COMT NRG1 PENK

Biological processes related to Cannabis Dependence according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 locomotory behavior GO:0007626 9.43 NRG1 PENK
2 sensory perception of pain GO:0019233 9.4 CNR1 PENK
3 response to nicotine GO:0035094 9.37 CNR1 PENK
4 response to morphine GO:0043278 9.32 CNR1 PENK
5 regulation of sensory perception of pain GO:0051930 9.26 COMT MGLL
6 arachidonic acid metabolic process GO:0019369 9.16 FAAH MGLL
7 response to lipopolysaccharide GO:0032496 9.13 CNR1 COMT PENK
8 startle response GO:0001964 8.62 NRG1 PENK

Molecular functions related to Cannabis Dependence according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 HCRT PENK
2 acylglycerol lipase activity GO:0047372 8.62 FAAH MGLL

Sources for Cannabis Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....